Pseudogout
Summary
Pseudogout is an acute crystal arthropathy caused by deposition of calcium pyrophosphate dihydrate (CPPD) crystals in articular cartilage and subsequent release into joint fluid. Unlike gout (monosodium urate crystals), pseudogout primarily affects older patients and classically involves the knee or wrist. The condition is clinically indistinguishable from septic arthritis and gout, making joint aspiration essential for diagnosis. Radiographic chondrocalcinosis (cartilage calcification) is highly supportive but not diagnostic.
Key Facts
- Definition: Acute inflammatory arthritis caused by CPPD crystal deposition
- Prevalence: Increases with age; 15-30% of elderly have radiographic chondrocalcinosis
- Key Joints: Knee (50%), wrist (30%), shoulders, ankles, elbows
- Crystal Features: Weakly positively birefringent rhomboid crystals (vs gout: negative needle)
- Radiographic Sign: Chondrocalcinosis — linear calcification in fibrocartilage and hyaline cartilage
- "3 H's": Associated with Hyperparathyroidism, Haemochromatosis, Hypomagnesaemia
Clinical Pearls
Blue = Positive = Pseudogout: Under polarised microscopy, CPPD crystals are rhomboid and weakly POSITIVELY birefringent (blue when parallel to compensator). Gout = negative needle (yellow when parallel).
Always Aspirate: Acute monoarthritis in an elderly patient is septic arthritis until proven otherwise. You CANNOT distinguish pseudogout from septic arthritis clinically — aspiration is mandatory.
Young Pseudogout = Metabolic Screen: CPPD disease in patients <55 years should prompt investigation for underlying metabolic causes: calcium, magnesium, ferritin, and parathyroid hormone.
Why This Matters Clinically
Pseudogout is a common cause of acute joint pain in elderly patients and is frequently encountered in hospital medicine. The critical clinical issue is distinguishing it from septic arthritis, which requires joint aspiration. Missing septic arthritis can lead to joint destruction, sepsis, and death.
Incidence & Prevalence
- Radiographic Chondrocalcinosis: 15-30% of people >70 years; 50% of people >90 years
- Symptomatic CPPD: Much less common; most chondrocalcinosis is asymptomatic
- Trend: Increasing with ageing population
Demographics
| Factor | Details |
|---|---|
| Age | Rare <55 years; prevalence increases dramatically with age |
| Sex | Equal male:female (unlike gout which is male-predominant) |
| Ethnicity | No significant differences |
| Geography | Higher prevalence in regions with hereditary forms (e.g., Chile, Slovakia) |
Risk Factors
Non-Modifiable:
- Advanced age (strongest factor)
- Family history (hereditary CPPD exists)
- Previous joint injury or surgery
- Pre-existing OA (CPPD deposits in damaged cartilage)
Modifiable/Metabolic:
| Condition | Mechanism | Screening Test |
|---|---|---|
| Hyperparathyroidism | Hypercalcaemia promotes crystal formation | Calcium, PTH |
| Haemochromatosis | Iron overload, inhibits pyrophosphatases | Ferritin, transferrin saturation |
| Hypomagnesaemia | Low Mg increases pyrophosphate solubility | Serum magnesium |
| Hypophosphataemia | Phosphate metabolism disruption | Phosphate |
| Hypothyroidism | Unclear mechanism | TFTs |
Mnemonic: "The 3 H's": Hyperparathyroidism, Haemochromatosis, Hypomagnesaemia
Mechanism
Step 1: Crystal Formation
- CPPD crystals form in cartilage matrix (particularly fibrocartilage)
- Favoured by high pyrophosphate concentration and appropriate calcium levels
- Deposits in menisci, TFCC, symphysis pubis, intervertebral discs
Step 2: Crystal Shedding ("Flare Trigger")
- Acute illness, surgery, trauma, or metabolic change
- Crystals shed from cartilage into synovial fluid
- Partial dissolution changes crystal surface properties
Step 3: Inflammatory Response
- CPPD crystals activate NLRP3 inflammasome in synovial macrophages
- IL-1β and IL-18 release → intense inflammation
- Neutrophil recruitment → acute synovitis
Step 4: Resolution
- Self-limiting over days to weeks
- Crystals may re-deposit or persist in fluid
- Recurrent attacks contribute to joint damage
Classification (Phenotypes)
| Phenotype | Clinical Features | Joints |
|---|---|---|
| Acute CPP Crystal Arthritis | Sudden onset, mimics gout/septic | Knee, wrist most common |
| Chronic CPP Crystal Inflammatory Arthritis | RA-like polyarthritis | Multiple joints |
| OA with CPPD | OA with superimposed acute attacks | Knees, hips, MCPs |
| Pseudo-Neuropathic | Severe joint destruction | Shoulder, knee |
| Asymptomatic Chondrocalcinosis | Incidental finding on X-ray | Any |
Anatomical Considerations
- Knee: Meniscal calcification; most common site of acute attacks
- Wrist: Triangular fibrocartilage (TFCC) calcification
- Symphysis pubis: Classic site of chondrocalcinosis on AP pelvis X-ray
- Cervical spine: Crowned dens syndrome (atlantoaxial calcification)
Symptoms
Typical Presentation:
Atypical Presentations:
Signs
Red Flags
[!CAUTION] Red Flags — Aspirate urgently and consider septic arthritis if:
- High fever (>38.5°C) or rigors
- Immunocompromised patient (diabetes, steroids, HIV)
- Prosthetic joint
- Post-procedural (after injection or surgery)
- Failure to improve with appropriate treatment
- Overlying skin infection
Structured Approach
General:
- Assess for systemic illness (fever, tachycardia)
- Look for features of metabolic causes (skin bronzing = haemochromatosis)
- Check other joints (polyarticular involvement)
Joint Examination:
- Inspect for swelling, erythema
- Palpate for warmth, effusion, tenderness
- Assess active and passive range of motion
- Check for instability or crepitus
Special Tests
| Test | Technique | Positive Finding | Significance |
|---|---|---|---|
| Joint Aspiration | Sterile aspiration of synovial fluid | Inflammatory fluid + CPPD crystals | DIAGNOSTIC |
| Polarised Microscopy | Examine fluid under polarised light | Weakly +ve birefringent rhomboids | Confirms CPPD |
| Effusion Assessment | Patellar tap, ballottement | Fluid present | Indication for aspiration |
| ROM Assessment | Active/passive movement | Pain-limited, guarding | Non-specific |
First-Line (Bedside)
- Joint aspiration — ESSENTIAL FOR DIAGNOSIS
- Temperature, HR, BP — assess for sepsis
Laboratory Tests
| Test | Expected Finding | Purpose |
|---|---|---|
| Synovial Fluid WBC | 10,000-50,000/μL (inflammatory) | Differentiate from non-inflammatory |
| Synovial Fluid Crystals | CPPD: rhomboid, weakly +ve birefringent | DIAGNOSTIC |
| Gram Stain & Culture | Negative (excludes sepsis) | MUST do on every aspirate |
| CRP/ESR | Elevated; non-specific | Monitor inflammation |
| FBC | Elevated WCC possible | Non-specific |
| Urate | Normal (rules out gout) | Differential diagnosis |
Metabolic Screen (if young or polyarticular):
- Calcium, PTH — hyperparathyroidism
- Ferritin, transferrin saturation — haemochromatosis
- Magnesium — hypomagnesaemia
- TFTs — hypothyroidism
- Phosphate — hypophosphataemia
Imaging
| Modality | Findings | Indication |
|---|---|---|
| X-ray | Chondrocalcinosis (linear cartilage calcification) | Supporting diagnosis |
| Ultrasound | Hyperechoic deposits in cartilage | Sensitive for chondrocalcinosis |
| CT | Calcification detail; crowned dens | Cervical spine symptoms |
| MRI | Synovitis, effusion, cartilage | Complex cases |
X-ray Chondrocalcinosis Sites
- Knee menisci (most common)
- Triangular fibrocartilage of wrist
- Symphysis pubis
- Intervertebral discs
- Achilles tendon insertion
Management Algorithm
ACUTE PSEUDOGOUT MANAGEMENT
↓
┌─────────────────────────────────────────────────┐
│ FIRST-LINE OPTIONS │
│ (Choose based on patient) │
│ │
│ • Intra-articular corticosteroid (preferred) │
│ - Methylprednisolone 40mg or Triamcinolone │
│ - Immediate relief; ideal for single joint │
│ │
│ • NSAIDs (if no contraindications) │
│ - Naproxen 500mg BD or Indomethacin 50mg TDS │
│ - Avoid in CKD, GI bleeding, CCF, elderly │
│ │
│ • Colchicine (alternative) │
│ - 500mcg BD-TDS │
│ - Watch for GI side effects │
│ - Reduce dose in CKD │
└─────────────────────────────────────────────────┘
↓
If Multiple Joints or Contraindications:
↓
┌─────────────────────────────────────────────────┐
│ SYSTEMIC CORTICOSTEROIDS │
│ │
│ • Prednisolone 30-40mg daily, taper over 7-14d │
│ • IM methylprednisolone if oral not possible │
└─────────────────────────────────────────────────┘
↓
PROPHYLAXIS (Recurrent Attacks)
↓
Low-dose colchicine 500mcg OD-BD
Acute/Emergency Management
Immediate Actions:
- Joint aspiration — diagnostic and therapeutic (draining inflammatory fluid reduces pressure)
- Send fluid for microscopy, Gram stain, culture
- Initiate treatment once sepsis excluded
Conservative Management
- Ice application to affected joint
- Rest and elevation
- Avoid weight-bearing if lower limb affected
Medical Management
| Drug Class | Drug | Dose | Notes |
|---|---|---|---|
| Intra-articular steroid | Methylprednisolone | 40-80mg | First-line for single joint |
| NSAIDs | Naproxen | 500mg BD for 7-10 days | Avoid in elderly, CKD, CVD |
| NSAIDs | Indomethacin | 50mg TDS for 7-10 days | GI protection with PPI |
| Colchicine | Colchicine | 500mcg BD-TDS | Alternative; GI side effects |
| Systemic steroids | Prednisolone | 30-40mg OD, tapering | Polyarticular or contraindications |
| Prophylaxis | Colchicine | 500mcg OD-BD | For recurrent attacks |
Chronic/Recurrent Disease
- No disease-modifying therapy available (unlike gout)
- Prophylactic colchicine reduces attack frequency
- Magnesium supplementation may help if deficient
- Treat underlying metabolic cause if identified
Disposition
- Admit if: Septic arthritis not excluded, systemic illness, unable to take oral meds
- Discharge if: Sepsis excluded, can take oral treatment, close follow-up arranged
- Follow-up: GP/Rheumatology in 1-2 weeks; metabolic screen if indicated
Immediate (Minutes-Hours)
| Complication | Incidence | Presentation | Management |
|---|---|---|---|
| Missed septic arthritis | Avoidable | Worsening sepsis | Urgent repeat aspiration, IV antibiotics |
| Haemarthrosis (post-aspiration) | Rare | Worsening swelling | Pressure, may need drainage |
Early (Days)
- Treatment failure: Consider alternative diagnosis or resistant case
- NSAID complications: GI bleeding, AKI, CCF exacerbation
- Colchicine toxicity: Diarrhoea, myopathy (especially with CKD)
Late (Weeks-Months)
- Recurrent attacks: Common; consider prophylaxis
- Chronic arthropathy: Progressive joint damage with repeated attacks
- Secondary OA: Accelerated by CPPD deposition
- Rare destructive arthropathy: Pseudo-neuropathic joint (shoulders, knees)
Natural History
Acute attacks are self-limiting, typically resolving over 1-3 weeks even without treatment. Recurrence is common. Chronic CPPD deposition contributes to joint degeneration over time. Unlike gout, there is no curative treatment — management is symptomatic.
Outcomes with Treatment
| Variable | Outcome |
|---|---|
| Acute attack resolution | 1-2 weeks with treatment |
| Recurrence | Common; 50% have recurrent attacks |
| Joint damage | Progressive with recurrent attacks |
| Mortality | Not directly fatal; acute attacks may indicate underlying illness |
Prognostic Factors
Good Prognosis:
- Single joint involvement
- Responsive to treatment
- No underlying metabolic cause
- Infrequent attacks
Poor Prognosis:
- Recurrent attacks
- Polyarticular disease
- Underlying metabolic disorder (if untreated)
- Severe joint damage at presentation
Key Guidelines
-
EULAR (2011) — Recommendations for diagnosis and management of CPPD. Emphasise aspiration for diagnosis; intra-articular steroid as first-line for acute attacks.
-
ACR/EULAR (2015 Updates) — Support colchicine for prophylaxis in recurrent disease; recommend metabolic screening in young patients.
Landmark Studies
McCarty & Hollander (1961) — Original description of CPPD crystals
- First identified CPPD as distinct from urate crystals
- Clinical Impact: Established pseudogout as separate entity from gout
Zhang et al. (2011) — EULAR systematic review
- Comprehensive review of CPPD diagnosis and management
- Key finding: Intra-articular corticosteroids effective; no disease-modifying therapy
- Clinical Impact: Established evidence-based management recommendations
Rosenthal & Ryan (2016) — Pathogenesis review
- Elucidated role of NLRP3 inflammasome in CPPD inflammation
- Clinical Impact: Explains why IL-1 inhibitors may work in refractory cases
Evidence Strength
| Intervention | Level | Key Evidence |
|---|---|---|
| Intra-articular corticosteroid | 1b | RCTs, EULAR recommendations |
| NSAIDs | 2a | Extrapolated from gout trials |
| Colchicine (acute) | 2b | Cohort studies, expert consensus |
| Colchicine (prophylaxis) | 2b | Observational studies |
What is Pseudogout?
Pseudogout is a condition where crystals build up in your joint cartilage and then suddenly cause intense pain and swelling. These crystals are made of calcium pyrophosphate (different from the uric acid crystals in regular gout). It's called "pseudo" (meaning false) gout because it causes very similar symptoms to gout but needs different treatment.
Why does it matter?
Pseudogout attacks can be extremely painful and make it hard to walk or use the affected joint. The main concern is that it looks exactly like a joint infection (septic arthritis), which is very serious. That's why doctors usually need to take a small sample of fluid from your joint to check for crystals and infection.
How is it treated?
-
Draining the joint: Taking fluid out provides immediate relief and allows testing to confirm the diagnosis.
-
Steroid injection: An injection into the joint is often the best treatment for a single swollen joint.
-
Anti-inflammatory tablets: NSAIDs (like ibuprofen or naproxen) or colchicine can reduce inflammation.
-
Steroids tablets: If the injection isn't suitable, steroid tablets work well.
-
No cure: Unlike gout, there's no treatment that removes the crystals permanently. Treatment focuses on managing attacks when they happen.
What to expect
- Attacks usually settle within 1-2 weeks with treatment
- You may have future attacks — this is normal
- If attacks are frequent, a daily low-dose medication can reduce them
When to seek help
See a doctor urgently if:
- You have sudden severe joint pain with swelling
- You have a fever with joint pain
- You recently had a joint injection or surgery
- The joint becomes red and hot
Primary Guidelines
- Zhang W, Doherty M, Bardin T, et al. European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis. Ann Rheum Dis. 2011;70(4):563-570. PMID: 21216817
Key Trials
-
Zhang W, Doherty M, Pascual E, et al. EULAR recommendations for calcium pyrophosphate deposition. Part II: management. Ann Rheum Dis. 2011;70(4):571-575. PMID: 21257615
-
Rosenthal AK, Ryan LM. Calcium Pyrophosphate Deposition Disease. N Engl J Med. 2016;374(26):2575-2584. PMID: 27355536
-
McCarthy DJ, Hollander JL. Identification of urate crystals in gouty synovial fluid. Ann Intern Med. 1961;54:452-460. PMID: 13773775
Further Resources
- American College of Rheumatology: rheumatology.org
- Radiopaedia — Chondrocalcinosis examples
Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate guidelines and specialists for patient care.